SEC Form 4
Belite Bio, Inc (BLTE) insider trading
In the 12 months to Oct 31, 2026, 5 BLTE insiders reported open-market sales of $40.6M across 27 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $40.6M
- 27 filings · 5 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 25 of 27
- $37.8M of $40.6M sold (93%)
Who traded BLTE, and when
- Sale
- Sale, pre-arranged (10b5-1)
BLTE daily close from Oct 31, 2025 to Oct 30, 2026, between $105.76 and $193.61, last $154.74. 27 sale and 0 purchase filings by 5 insiders, marked at their filing dates. Yu-Hsin Lin, Chief Executive Officer: sold $20.8M across 3 filings, first filed Apr 13, 2026, last Sep 9, 2026. Hao-Yuan Chuang, Chief Financial Officer: sold $14.0M across 3 filings, first filed Apr 13, 2026, last Sep 9, 2026. Hendrik Peter Scholl, Chief Medical Officer: sold $2.9M across 3 filings, first filed Jun 17, 2026, last Oct 5, 2026. Nathan L. Mata, Chief Scientific Officer: sold $2.7M across 17 filings, first filed Apr 16, 2026, last May 8, 2026. Wan-Shan Chen, Director: sold $198.5K across 1 filing, first filed Apr 13, 2026, last Apr 13, 2026.
Largest mark · tap a row for others
Yu-Hsin Lin · Chief Executive Officer
Sale $19,082,549
100,435 ADS at $190.00 avg
Filed Sep 9, 2026 · traded Sep 4
Pre-arranged (10b5-1) · close on filing date $183.16
Yu-Hsin Lin · Chief Executive Officer
Chief Executive Officer
$20.8M soldHao-Yuan Chuang · Chief Financial Officer
Chief Financial Officer
$14.0M soldHendrik Peter Scholl · Chief Medical Officer
Chief Medical Officer
$2.9M soldNathan L. Mata · Chief Scientific Officer
Chief Scientific Officer
$2.7M soldWan-Shan Chen · Director
Director
$198.5K soldOpen-market trades
27 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Yu-Hsin Lin | Chief Executive Officer | $20.8M | — | 3 | 100% of sales | |
| Hao-Yuan Chuang | Chief Financial Officer | $14.0M | — | 3 | 100% of sales | |
| Hendrik Peter Scholl | Chief Medical Officer | $2.9M | — | 3 | 3% of sales | |
| Nathan L. Mata | Chief Scientific Officer | $2.7M | — | 17 | 100% of sales | |
| Wan-Shan Chen | Director | $198.5K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Hendrik Peter Scholl Chief Medical Officer | SalePre-arranged (10b5-1) | 500 | $165.32 | $82.7K | 14,516 | |
traded | Hao-Yuan Chuang Chief Financial Officer | SalePre-arranged (10b5-1) | 67,395 | $189.98 | $12.8M | 26,038 | |
traded | Yu-Hsin Lin Chief Executive Officer | SalePre-arranged (10b5-1) | 100,435 | $190.00 | $19.1M | 93,734 | |
traded | Yu-Hsin Lin Chief Executive Officer | SalePre-arranged (10b5-1) | 365 | $180.35 | $65.8K | 170,569 | |
traded | Hao-Yuan Chuang Chief Financial Officer | SalePre-arranged (10b5-1) | 367 | $180.35 | $66.2K | 93,433 | |
traded | Hendrik Peter Scholl Chief Medical Officer | Sale | 10,000 | $145.24 | $1.5M | 15,000 | |
traded | Hendrik Peter Scholl Chief Medical Officer | Sale | 10,000 | $140.57 | $1.4M | 25,000 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 666 | $153.21 | $102.0K | 12 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $153.84 | $153.8K | 866 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $155.50 | $155.5K | 2,546 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $155.64 | $155.6K | 3,398 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $155.78 | $155.8K | 3,980 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $156.97 | $157.0K | 5,624 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $155.82 | $155.8K | 6,388 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $159.16 | $159.2K | 6,929 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $162.64 | $162.6K | 8,111 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $159.56 | $159.6K | 8,666 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $166.28 | $166.3K | 10,399 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $170.38 | $170.4K | 11,373 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $166.00 | $166.0K | 12,192 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $163.59 | $163.6K | 12,666 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $160.38 | $160.4K | 15,030 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $161.63 | $161.6K | 14,582 | |
traded | Nathan L. Mata Chief Scientific Officer | SalePre-arranged (10b5-1) | 1,000 | $168.30 | $168.3K | 16,283 | |
traded | Hao-Yuan Chuang Chief Financial Officer | SalePre-arranged (10b5-1) | 6,200 | $181.50 | $1.1M | 94,091 | |
traded | Wan-Shan Chen Director | SalePre-arranged (10b5-1) | 1,100 | $180.43 | $198.5K | 9,096 | |
traded | Yu-Hsin Lin Chief Executive Officer | SalePre-arranged (10b5-1) | 9,200 | $181.45 | $1.7M | 174,134 |
GET /stocks/filings/vX/form-4?tickers=BLTE&filing_date.gte=2025-10-31&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"BLTE"
],
"issuer_cik": "0001889109",
"owner_cik": "0002113223",
"accession_number": "0001193125-26-414643",
"form_type": "4",
"filing_date": "2026-10-05",
"period_of_report": "2026-10-01",
"issuer_name": "BELITE BIO, INC",
"issuer_trading_symbol": "BLTE",
"owner_name": "Scholl Hendrik Peter",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Medical Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "American depositary share",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 200,
"transaction_price_per_share": 163.625,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 14800,
"transaction_value": 32725,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "By Bioptima Ltd.",
"footnotes": [
{
"id": "F1",
"description": "Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer."
},
{
"id": "F2",
"description": "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/25/2026."
},
{
"id": "F3",
"description": "Represents the weighted average price of shares sold at prices that ranged from $163.6 to $163.65. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price."
}
]
},
{
"tickers": [
"BLTE"
],
"issuer_cik": "0001889109",
"owner_cik": "0002113223",
"accession_number": "0001193125-26-414643",
"form_type": "4",
"filing_date": "2026-10-05",
"period_of_report": "2026-10-01",
"issuer_name": "BELITE BIO, INC",
"issuer_trading_symbol": "BLTE",
"owner_name": "Scholl Hendrik Peter",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Medical Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "American depositary share",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 120,
"transaction_price_per_share": 165.4935,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 14656,
"transaction_value": 19859.22,
"not_subject_to_section_16": false,
"direct_or_indirect": "I",
"nature_of_ownership": "By Bioptima Ltd.",
"footnotes": [
{
"id": "F1",
"description": "Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer."
},
{
"id": "F2",
"description": "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/25/2026."
},
{
"id": "F5",
"description": "Represents the weighted average price of shares sold at prices that ranged from $165 to $165.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 5 records
- Other5 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Belite Bio, Inc's CEO sold stock?
Yes. Yu-Hsin Lin (CEO) sold 110,000 shares ($20.8M) between Apr 2026 and Sep 2026, all under a pre-arranged 10b5-1 plan.
How current is BLTE’s insider data?
These are BLTE Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track BLTE insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for BLTE every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.